ADAmandine Descat

Amandine Descat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amandine Descat has a total of 150 co-authors. Here are the top co-authors by number of shared publications:

  • Bart Staels

    Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille

    4 shared publications
  • Jean-François Goossens

    Univ Lille, ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et Technologies Associées, F-59000, Lille, France; Univ Lille, Plateau de spectrométrie de masse - ULR 7365 - GRITA - Groupe de Recherche sur les Formes Injectables et Technologies Associées, F-59000, Lille, France

    4 shared publications
  • Mostafa Kouach

    CHU Lille, ULR 7365 GRITA—Groupe de Recherche sur les formes Injectables et les Technologies Associées, Univ. Lille , Lille F-59000

    4 shared publications
  • Elsa Heyman

    Univ. Lille, Univ. Artois, Univ. Littoral Côte d’Opale, ULR 7369 - URePSSS - Unité de Recherche Pluridisciplinaire Sport Santé Société, Lille, France

    3 shared publications
  • Hélène Blasco

    Service de Biochimie et Biologie Moléculaire, CHRU de Tours, 37044 Tours, France

    3 shared publications
  • Jean-François Goossens

    Université de Lille, CHU Lille, ULR 7365 – GRITA – Groupe de Recherche sur les formes Injectables et les Technologies Associées Lille France

    3 shared publications

Latest Publications

  • Développements de méthodes d'analyse des plastifiants de type phtalates et des acides biliaires dans des matrices biologiques : applications dans différents contextes physiopathologiques

    by Amandine Descat

    Ce travail de thèse s'articule autour de deux axes :1/ Les plastifiants, y compris les phtalates, ont été identifiés comme cancérigènes, mutagènes, reprotoxiques (CMR) de catégorie 1b et comme perturbateurs endocriniens. Le di-2-éthylhexyle phtalate (DEHP) est l'un des plastifiants les plus courants et est généralement associé au polychlorure de vinyle (PVC) dans les dispositifs médicaux. Le DEHP n'étant pas lié de manière covalente au PVC, il peut facilement migrer dans des matrices lipophiles et atteindre ensuite la circulation sanguine. Il est métabolisé par le foie en mono-2-éthylhexyle phtalate (MEHP), tout aussi toxique. Ces dernières années, des plastifiants alternatifs au DEHP ont été développés, notamment le di-2-éthylhexyl téréphtalate (DEHT), qui est métabolisé in vivo en mono-2-éthylhexyl téréphtalate (MEHT).La première partie de ce travail de thèse a consisté à développer des méthodes de dosage des plastifiants et de leurs métabolites dans diverses matrices biologiques, comme par exemple le plasma. Deux méthodes LC-MS/MS ont été développées pour la détermination du DEHP et du MEHP ainsi que des métabolites du DEHT. L'ionisation par spectrométrie de masse du DEHT étant très faible, une méthode LC-UV a été développée pour quantifier ce téréphtalate. Ces méthodes ont permis d'estimer le relargage du DEHP et du DEHT à partir de poches de sang et le dosage de leurs métabolites primaires dans les produits sanguins.2/ Les acides biliaires (AB) constituent une large famille de stéroïdes composée de nombreuses espèces. Ils sont synthétisés dans le foie et l'intestin et représentent la voie principale de catabolisme du cholestérol. Le 7a-hydroxy-4-cholesten-3-one (C4) est le précurseur des AB. Les AB jouent un rôle essentiel dans l'absorption des lipides mais également dans la signalisation cellulaire, étant ligands du récepteur nucléaire « Farnesoid X receptor » (FXR) et/ou du récepteur membranaire couplé aux protéines G, TGR5. Ces récepteurs, et donc leurs ligands, sont impliqués dans la régulation de l'homéostasie du glucose, des lipides et de la dépense énergétique. Toute modulation du profil des AB peut donc conduire à une modification de l'homéostasie métabolique.La deuxième partie de ce travail de thèse a consisté à développer deux méthodes de dosage par LC-MS/MS de 31 espèces d'AB et du C4 dans différentes matrices biologiques, dont le plasma. Une méthode spécifique permettant le dosage d'AB dérivés du LCA, récemment décrits, dans du contenu caecal est en cours d'optimisation. Ces méthodes ont permis d'analyser les variations du profil des AB dans divers contextes de la maladie cardiométabolique (obésité, insulino-résistance, diabète de type 2, NAFLD).Pour conclure, les méthodes d'analyse développées pour la quantification des plastifiants et des AB ont été validées et appliquées dans des études précliniques et cliniques. De manière intéressante, des données de la littérature ainsi que des essais préliminaires de transfection transitoire ont montré que des phtalates et leurs métabolites modulent l'activité du récepteur alpha activé par les proliférateurs de peroxysomes (PPARa) régulateur clé de l'homéostasie métabolique et de l'expression de l'enzyme CYP7A1 (enzyme majeure de la synthèse hépatique des AB). Les outils analytiques développés dans cette thèse permettent d'ouvrir des perspectives originales d'étude des effets des phtalates sur l'homéostasie métabolique via la régulation du métabolisme des AB.L'ensemble de ces travaux a permis de lier développements analytiques et applications dans le domaine de la biologie et de la santé.

  • Maternal Obesity Increases Breast Milk Bile Acid Levels

    by Lucie Marousez, Amandine Descat, Mostafa Kouach, Thameur Rakza, Philippe Deruelle, Bart Staels, Jean-FrançoIs Goossens, Anne Tailleux, Delphine Eberlé

    Context: Breast milk (BM) provides the optimal combination of essential nutrients and bioactive molecules for infant growth and development. However, accumulating evidence from our group and others indicates that maternal factors, such as obesity, can alter BM composition, potentially affecting offspring health outcomes. Bile acids (BA), both primary and secondary, have been identified in human BM but the precise composition and their role in BM remain largely underexplored. Objective: In this study, we analyzed BA profiles in BM and plasma in lactating mothers with obesity or not, across 2 independent clinical cohorts. Methods: BM and plasma samples were collected from breastfeeding women classified as normal weight (N) or with obesity (O). BA concentrations were quantified by reverse phase liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Results: BAs were present in BM, primarily as glyco- and tauro-conjugated of the primary BAs cholic (CA) and chenodeoxycholic acid (CDCA), although at lower levels than in plasma under normal-weight conditions. Maternal obesity led to a marked increase in total BM BA levels while plasma BA concentrations and composition remained unchanged. Additionally, BM BA levels were positively correlated with maternal pre-pregnancy body mass index, circulating leptin (a marker of adiposity), and insulin levels. Conclusion: Our findings identify maternal obesity as a significant modifier of BM BA composition, with potential implications for neonatal digestion, maturation, and health. Further research is warranted to elucidate the impact of these alterations on infant health and development.


  • Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis

    by Fanny Lalloyer, Denis A. Mogilenko, Ann Verrijken, Joel T. Haas, Antonin Lamazière, Mostafa Kouach, Amandine Descat, Sandrine Caron, Emmanuelle Vallez, Bruno Derudas, et al.


  • Open Access

    Control of lipid metabolism by the dynamic and nutrient‐dependent post‐translational modification O‐GlcNAcylation

    by Céline Schulz, Quentin Lemaire, Alexandre Berthier, Amandine Descat, Mostafa Kouach, Anne‐Sophie Vercoutter‐Edouart, Ikram El Yazidi‐Belkoura, Stéphan Hardivillé, Jean‐François Goossens, Philippe Lefebvre, et al.

    O‐GlcNAcylation is a post‐translational modification belonging to the large group of glycosylations. It consists of the modification of cytoplasmic, nuclear, and mitochondrial proteins with a single N‐acetylglucosamine residue by O‐GlcNAc transferase (OGT). Despite its structural simplicity, O‐GlcNAcylation orchestrates many functions inside the cell. This modification regulates fatty acids synthesis, fat storage, and utilization. The generation of white and brown adipocyte‐OGT knock‐out mice has highlighted the marked interference of O‐GlcNAcylation in adiposity and, as a consequence, in metabolic pathologies. OGT is more especially involved in the regulation of lipolysis, and thermogenesis in brown adipose tissue. In addition, O‐GlcNAcylation directly regulates fatty acid synthase, the main enzyme responsible for fatty acids synthesis, and other lipogenic enzymes and transcription factors. Nevertheless, only a few studies reported connections between O‐GlcNAcylation and homeostasis of cholesterol or its derivatives. This knowledge gap is surprising due to the crucial importance of cholesterol in structuring animal biological membranes and as a precursor of a wide variety of biological compounds. Here, we review the current literature about this topic and discuss future prospects in the field.Key points: As a PTM, O‐GlcNAcylation exponentially expands protein functions. O‐GlcNAcylation orchestrates many biological functions in living beings including metabolic fluxes. O‐GlcNAcylation is crucial for fat storage and mobilization, and for fatty acid synthesis but its function in the metabolism of other lipid compounds is less documented.


  • High‐performance liquid chromatography–ultraviolet detection method to evaluate the migration of di(2‐ethylhexyl) terephthalate and its metabolite from polyvinyl chloride bag in four labile blood products

    by Aurélie Thelliez, Amandine Descat, Pauline Bouchot, Mostafa Kouach, Jean‐François Goossens, Bertrand Decaudin, Marie Lecoeur

    A liquid chromatography with UV detection method has been developed and validated for the quantitation of di(2‐ethylhexyl)terephthalate, a blood bag plasticizer, and its monoester metabolite, mono(2‐ethylhexyl)terephthalate, in the four labile blood products: whole blood, red cells concentrate, plasma and platelet concentrate. Quantitation thresholds were compared with those obtained using the more conventional tandem mass spectrometry detection and revealed that UV performed better than mass spectrometry for the quantitation of di(2‐ethylhexyl)terephthalate. Liquid‐liquid extraction was selected for sample preparation. Recoveries ranged from 101 to 106 and from 80 to 83%, for di(2‐ethylhexyl)terephthalate and mono(2‐ethylhexyl)terephthalate, respectively, depending on the labile blood product. Repeatability and intermediate precision expressed as relative standard deviation were lower than 20% at the lower limit of quantitation and ranged from 1.9 to 11.2% for the other concentration levels. Regarding the trueness, bias ranged from ‐13.6 to 11.8%. The method was validated considering a total error of ± 20%. Lower limits of quantitation ranged from 500 to 680 nM for di(2‐ethylhexyl)terephthalate and were equal to 500 nM for mono(2‐ethylhexyl)terephthalate. Migration of di(2‐ethylhexyl)terephthalate from polyvinyl chloride blood bags was investigated and mono(2‐ethylhexyl)terephthalate concentrations were determined in each labile blood product.


  • Circulating biomarkers of nitric oxide bioactivity and impaired muscle vasoreactivity to exercise in adults with uncomplicated type 1 diabetes

    by Elodie Lespagnol, Sémah Tagougui, Bernadette O. Fernandez, Farid Zerimech, Régis Matran, Patrice Maboudou, Serge Berthoin, Amandine Descat, Isabelle Kim, Mehdi Pawlak-Chaouch, et al.

    Aims/hypothesis Early compromised endothelial function challenges the ability of individuals with type 1 diabetes to perform normal physical exercise. The exact mechanisms underlying this vascular limitation remain unknown, but may involve either formation or metabolism of nitric oxide (NO), a major vasodilator, whose activity is known to be compromised by oxidative stress. Methods Muscle microvascular reactivity (near-infrared spectroscopy) to an incremental exhaustive bout of exercise was assessed in 22 adults with uncomplicated type 1 diabetes (HbA1c 64.5 ± 15.7 mmol/mol; 8.0 ± 1.4%) and in 21 healthy individuals (18–40 years of age). NO-related substrates/metabolites were also measured in the blood along with other vasoactive compounds and oxidative stress markers; measurements were taken at rest, at peak exercise and after 15 min of recovery. Demographic characteristics, body composition, smoking status and diet were comparable in both groups. Results Maximal oxygen uptake was impaired in individuals with type 1 diabetes compared with in healthy participants (35.6 ± 7.7 vs 39.6 ± 6.8 ml min−1 kg−1, p < 0.01) despite comparable levels of habitual physical activity (moderate to vigorous physical activity by accelerometery, 234.9 ± 160.0 vs 280.1 ± 114.9 min/week). Compared with non-diabetic participants, individuals with type 1 diabetes also displayed a blunted exercise-induced vasoreactivity (muscle blood volume at peak exercise as reflected by ∆ total haemoglobin, 2.03 ± 5.82 vs 5.33 ± 5.54 μmol/l; interaction ‘exercise’ × ‘group’, p < 0.05); this was accompanied by lower K+ concentration (p < 0.05), reduced plasma l-arginine (p < 0.05)—in particular when HbA1c was high (mean estimation: −4.0, p < 0.05)—and lower plasma urate levels (p < 0.01). Nonetheless, exhaustive exercise did not worsen lipid peroxidation or other oxidative stress biomarkers, and erythrocytic enzymatic antioxidant resources were mobilised to a comparable extent in both groups. Nitrite and total nitrosation products, which are potential alternative NO sources, were similarly unaltered. Graphical abstract Conclusions/interpretation Participants with uncomplicated type 1 diabetes displayed reduced availability of l-arginine, the essential substrate for enzymatic nitric oxide synthesis, as well as lower levels of the major plasma antioxidant, urate. Lower urate levels may reflect a defect in the activity of xanthine oxidase, an enzyme capable of producing NO from nitrite under hypoxic conditions. Thus, both canonical and non-canonical NO production may be reduced. However, neither of these changes exacerbated exercise-induced oxidative stress. Trial registration clinicaltrials.gov NCT02051504


  • Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes

    by Oscar Chávez-Talavera, Matthieu Wargny, Matthieu Pichelin, Amandine Descat, Emmanuelle Vallez, Mostafa Kouach, Edith Bigot-Corbel, Marielle Joliveau, Jean-François Goossens, Cédric Le May, et al.


  • New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease

    by Nicolas Sergeant, Valérie Vingtdeux, Sabiha Eddarkaoui, Marion Gay, Caroline Evrard, Nicolas Le Fur, Cyril Laurent, Raphaelle Caillierez, Hélène Obriot, Paul-Emmanuel Larchanché, et al.


  • Plasma asymmetric dimethylarginine concentrations are not related to differences in maximal oxygen uptake in endurance trained and untrained men

    by Mehdi Pawlak‐Chaouch, Julien Boissière, Désiré Munyaneza, Semah Tagougui, François‐Xavier Gamelin, Grégory Cuvelier, Elsa Heyman, Jean‐François Goossens, Amandine Descat, Serge Berthoin, et al.

    New Findings What is the central question of this study? Is there an association of plasma concentration of asymmetric dimethylarginine, which is related to exercise capacity in patients with cardiovascular diseases, with oxygen delivery and subsequently exercise capacity in healthy subjects in the absence of the potentially confounding influence of inflammation and oxidative stress? What is the main finding and its importance? Plasma asymmetric dimethylarginine concentrations are not related to exercise capacity in healthy subjects, while O2 delivery in the working skeletal muscle during the maximal graded‐exercise test is not associated with any of the l‐arginine analogues. ADMA alone does not play a crucial role in local muscle perfusion and in maintaining exercise capacity. Abstract Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthesis that could limit oxygen (O2) delivery in the working skeletal muscles by altering endothelium‐dependent vasodilatation. Exercise capacity is associated with plasma ADMA concentrations in patients with cardiovascular diseases, but this issue has still not been investigated in healthy subjects. We aimed to determine whether plasma ADMA concentrations were negatively associated with exercise capacity in young healthy male subjects. Ten men with maximal oxygen uptake () > 65 mL kg−1 min−1 were included in the high exercise capacity group (HI‐FIT), and 10 men with < 45 mL kg−1 min−1 were included in the low exercise capacity group (LO‐FIT). Plasma ADMA and other l‐arginine analogue concentrations were measured before and after a maximal graded‐exercise test by liquid chromatography–tandem mass spectrometry. Microvascular O2 delivery during exercise was estimated through the pattern from the sigmoid model of muscle deoxygenation in the vastus lateralis measured by near infrared spectroscopy. was 60% higher in the HI‐FIT group (median: 70.2 mL kg−1 min−1; IQR: 68.0–71.9 mL kg−1 min−1) than in the LO‐FIT group (median: 43.8 mL kg−1 min−1; IQR: 34.8–45.3 mL kg−1 min−1). Plasma ADMA concentrations did not differ between the LO‐FIT and HI‐FIT groups before (0.50 ± 0.06 vs. 0.54 ± 0.07 μmol L−1, respectively) and after the maximal incremental exercise test (0.49 ± 0.08 vs. 0.55 ± 0.03 μmol L−1, respectively). There was no significant association of plasma ADMA concentrations with the pattern of local muscle deoxygenation and exercise capacity. Exercise capacity and microvascular O2 delivery are not related to plasma ADMA concentrations in young healthy male subjects. Our findings show that ADMA does not play a crucial role in local muscle perfusion and in maintaining exercise capacity without pathological conditions.